Keyphrases
Vulnerability
100%
Medulloblastoma
100%
H3K27 Acetylation
100%
Bromodomain
100%
Radiotherapy Resistance
100%
H3K27me3
45%
Radiation Resistance
27%
Radiotherapy Response
27%
EphA2
18%
H3K27ac
18%
AKT Pathway
18%
Tumor
9%
Overexpression
9%
Bcl-xL
9%
Overall Survival
9%
Improved Outcomes
9%
Histone
9%
Molecular Pathways
9%
Therapeutic Approaches
9%
Transcriptional Profiling
9%
Treatment Strategy
9%
Enhancer of Zeste Homolog 2 (EZH2)
9%
Genomic Loci
9%
Novel Mechanism
9%
Pro-survival
9%
Relapse Rate
9%
Epigenetic Mechanisms
9%
Epigenetic Profiling
9%
Genomic Profiling
9%
Guided Therapy
9%
Radioresistant
9%
Transcriptional Profile
9%
Apoptotic Response
9%
Epigenetic Marks
9%
Group 3 Medulloblastoma
9%
Epigenetic Switch
9%
Medulloblastoma Subgroups
9%
Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit
9%
Biochemistry, Genetics and Molecular Biology
Epigenetics
100%
Radiosensitivity
100%
Bromodomain
100%
Upregulation
66%
Protein Kinase B
66%
Enhancer Region
33%
Genetics
33%
Gene Expression Profiling
33%
Overall Survival
33%
EZH2
33%
Bcl-xL
33%
Epigenetic Mechanism
33%
Polycomb Repressive Complex 2
33%
Genomics
33%
Histone
33%
Neuroscience
Medulloblastoma
100%
Bromodomain
100%
Radiation Therapy
100%
Protein Kinase B
16%
Cell Signaling
8%
Enhancer Region
8%
Epigenetic Mechanism
8%
Histone
8%
Polycomb Repressive Complex 2
8%
Medicine and Dentistry
Medulloblastoma
100%
Radiation Therapy
100%
Radiosensitivity
25%
Upregulation
16%
Protein Kinase B
16%
Neoplasm
8%
Gene Expression Profiling
8%
Overall Survival
8%
Histone
8%
Recurrence Risk
8%
Enhancer Region
8%
Bcl-xL
8%
Cell Signaling Pathway
8%
Epigenetic Mechanism
8%
Predictive Marker
8%
Polycomb Repressive Complex 2
8%